Fig 1.
Eligibility criteria for publications included in systematic review.
Data on efficacy was defined as (the) “reporting of change in clinical status (relapse frequency, disability progression, behavioural symptoms) or changes in biomarkers of clinical status (magnetic resonance imaging (MRI), blood, cerebral spinal fluid (CSF))”.
Table 1.
Scoring method for evaluation of study quality.
Fig 2.
Selection process for publications & interventions.
Fig 3.
Effect of shortlisted interventions on neurobehavioural and pathological outcomes in EAE.
Symbols represent the point estimates of efficacy for interventions. Symbol sizes represent the log10 of the number of animals contributing to that comparison. The vertical line represents the line of no effect.
Table 2.
Candidate interventions excluded during short-listing.
Table 3.
Short-listed interventions ranked by overall drug scores.
Table 4.
Drugs excluded in committee review phase.
Table 5.
Final recommendations as candidate oral neuroprotective interventions for progressive MS.